Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 January 2018Website:
http://www.adicetbio.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:30:11 GMTDividend
Analysts recommendations
Institutional Ownership
ACET Latest News
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally.
Adicet Bio (ACET) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
In most cases, investors should stay away from penny stocks. They're wild, they're unpredictable and they tend to lose their stakeholders money more so than they return.
The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Adicet Bio (NASDAQ: ACET ) just reported results for the fourth quarter of 2023. Adicet Bio reported earnings per share of -69 cents.
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
High-risk stocks could potentially turn the tables for investors willing to stomach the risk. Moreover, as the Nasdaq Composite hit a fresh high last Friday, ahead of its 2021 peak, the market's appetite for risk continues to grow.
Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
What type of business is Adicet Bio?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
What sector is Adicet Bio in?
Adicet Bio is in the Healthcare sector
What industry is Adicet Bio in?
Adicet Bio is in the Biotechnology industry
What country is Adicet Bio from?
Adicet Bio is headquartered in United States
When did Adicet Bio go public?
Adicet Bio initial public offering (IPO) was on 26 January 2018
What is Adicet Bio website?
https://www.adicetbio.com
Is Adicet Bio in the S&P 500?
No, Adicet Bio is not included in the S&P 500 index
Is Adicet Bio in the NASDAQ 100?
No, Adicet Bio is not included in the NASDAQ 100 index
Is Adicet Bio in the Dow Jones?
No, Adicet Bio is not included in the Dow Jones index
When does Adicet Bio report earnings?
The next expected earnings date for Adicet Bio is 09 August 2024